Skip to main content
. 2023 Nov 30;109(6):1726–1740. doi: 10.3324/haematol.2023.283559

Figure 6.

Figure 6.

Targeting MYC reduced acute lymphoblastic leukemia progression caused by mutIL7Rαand mutNRAS. RAG1-/- mice injected with thymocytes transduced with mutIL7R and mutNRAS, were treated with volasertib. (A) Percentage of GFP leukemic cell expression in blood and spleen in either Control-no treatment (N=6) or treated with 10 mg/kg volasertib (N=6). (B) White blood cell (WBC) count in the spleen and blood, spleen weight and percentage of loss or gain body weights in mice treated with or without 10 mg/kg volasertib. (C) RAG1-/- were injected with mutIL7R and mutNRAS thymocytes, Twenty-four hours after mice were treated with either buffers alone (no treatment), volasertib (10 mg/kg), venetoclax (15 mg/kg) or with both volasertib and venetoclax. (N=5 in each group), mice were euthanized when they showed morbid symptoms and analyzed for GFP leukemic cells in the blood by flow cytometry: representative flow image (top) and quantification of GFP leukemic cells percentage in each group (bottom).